Aug 30 2012
Elan Corporation, plc (NYSE:ELN) today announced that it has commenced a
Phase 2, placebo-controlled, safety and efficacy study of oral ELND005
as an adjunctive maintenance treatment in patients with Bipolar I
Disorder (BPD 1) to delay the time to occurrence of mood episodes. The
first patient has been dosed in the study.
Bipolar I Disorder (BPD 1) is a severe form of BPD, also commonly known
as manic depressive illness. It is a psychiatric disorder characterized
by excessive swings in a person's mood and energy affecting their
ability to function. BPD is a lifetime recurrent disorder with cycles of
dramatic mood swings of highs and lows, often with periods of normal
moods in between. The periods of highs and lows are called episodes of
mania and depression. BPD is also associated with increased
cardiovascular morbidity and suicide risk. The US and EU population of
BPD patients is estimated at approximately 3.5 million.
With the first patient now dosed in a Phase 2 trial, Transition
Therapeutics Inc will receive a one time clinical milestone payment of
$11 million.
COVID-19 vaccines show moderate success in preventing long COVID in kids